Trade bluebird bio, Inc. - BLUE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.10 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.12 |
| Open | 4.08 |
| 1-Year Change | 348.35% |
| Day's Range | 4.03 - 4.14 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 4.07 | 0.02 | 0.49% | 4.05 | 4.16 | 4.03 |
| Apr 24, 2025 | 4.12 | 0.08 | 1.98% | 4.04 | 4.15 | 3.95 |
| Apr 23, 2025 | 4.01 | -0.36 | -8.24% | 4.37 | 4.52 | 4.01 |
| Apr 22, 2025 | 4.28 | 0.46 | 12.04% | 3.82 | 4.36 | 3.82 |
| Apr 21, 2025 | 3.84 | -0.23 | -5.65% | 4.07 | 4.07 | 3.81 |
| Apr 17, 2025 | 4.08 | -0.03 | -0.73% | 4.11 | 4.16 | 4.06 |
| Apr 16, 2025 | 4.13 | 0.13 | 3.25% | 4.00 | 4.18 | 3.93 |
| Apr 15, 2025 | 4.44 | -0.22 | -4.72% | 4.66 | 4.70 | 4.36 |
| Apr 14, 2025 | 4.74 | -0.13 | -2.67% | 4.87 | 5.07 | 4.60 |
| Apr 11, 2025 | 5.05 | 0.55 | 12.22% | 4.50 | 5.10 | 4.45 |
| Apr 10, 2025 | 4.55 | -0.15 | -3.19% | 4.70 | 4.71 | 4.47 |
| Apr 9, 2025 | 4.74 | 0.09 | 1.94% | 4.65 | 5.08 | 4.58 |
| Apr 8, 2025 | 4.76 | -0.06 | -1.24% | 4.82 | 5.12 | 4.72 |
| Apr 7, 2025 | 4.70 | -0.09 | -1.88% | 4.79 | 5.21 | 4.50 |
| Apr 4, 2025 | 4.72 | -0.11 | -2.28% | 4.83 | 4.95 | 4.63 |
| Apr 3, 2025 | 4.79 | 0.01 | 0.21% | 4.78 | 5.09 | 4.76 |
| Apr 2, 2025 | 4.87 | -0.32 | -6.17% | 5.19 | 5.34 | 4.78 |
| Apr 1, 2025 | 5.14 | 0.35 | 7.31% | 4.79 | 5.32 | 4.73 |
| Mar 31, 2025 | 4.86 | 0.46 | 10.45% | 4.40 | 5.38 | 4.25 |
| Mar 28, 2025 | 4.06 | 0.47 | 13.09% | 3.59 | 4.31 | 3.59 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Bluebird Company profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
455 Grand Union Boulevard
SOMERVILLE
MASSACHUSETTS 02145
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com